Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

189
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
189
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

770
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
770
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

12.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diltiazem N-oxide, a novel ischaemia-activated prodrug, prevents ischaemia-induced ventricular fibrillation without off-target adverse effects.

British journal of pharmacology·2026
Same author

Discovery of Potent PDE4 Inhibitors with 3(2H)-Pyridazinone Scaffold: Synthesis, In Silico Studies and In Vitro/Vivo Evaluation.

Molecules (Basel, Switzerland)·2026
Same author

Coprogen B from <i>Talaromyces marneffei ΔsreA</i>: Rapid Iron Chelation and Favorable Partitioning to Deferoxamine.

International journal of molecular sciences·2025
Same author

Synthetic Small-Molecule Ligands Targeted to Adenosine Receptors: Is There Potential Towards Ischemic Heart Disease?

Cells·2025
Same author

Development of small-molecule fluorescent probes targeting neutrophils <i>via N</i>-formyl peptide receptors.

RSC medicinal chemistry·2025
Same author

3,8-Disubstituted Pyrazolo[1,5-a]quinazoline as GABA<sub>A</sub> Receptor Modulators: Synthesis, Electrophysiological Assays, and Molecular Modelling Studies.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Jul 21, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K

PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.

Jian Jin1, Francesca Mazzacuva2, Letizia Crocetti3

  • 1Institute of Pharmaceutical Science, King's College London, Stamford Street, London SE1 9NH, UK.

International Journal of Molecular Sciences
|July 29, 2023
PubMed
Summary

Cyclic nucleotide phosphodiesterases 4 (PDE4) inhibitors are explored for treating respiratory and autoimmune diseases. This review details medicinal chemistry efforts in designing effective PDE4 inhibitors, focusing on structure, efficacy, and therapeutic potential.

Keywords:
PDE4 inhibitorsPDE4 selectivitydual activityphosphodiesterases 4respiratory diseasesstructural analysis

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

537
A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

9.6K

Related Experiment Videos

Last Updated: Jul 21, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

537
A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

9.6K

Area of Science:

  • Medicinal Chemistry
  • Enzymology
  • Pharmacology

Background:

  • Cyclic nucleotide phosphodiesterases 4 (PDE4) enzymes hydrolyze cAMP.
  • PDE4 inhibition is a therapeutic strategy for respiratory diseases (COPD, asthma) and autoimmune disorders (psoriasis).
  • Discovering novel PDE4 inhibitors remains a key focus in drug discovery.

Purpose of the Study:

  • To review the medicinal chemistry of PDE4 inhibitor design and development.
  • To analyze chemical classes, structural aspects, and binding properties of PDE4 inhibitors.
  • To evaluate inhibitory efficacy, PDE4 selectivity, and therapeutic potential.

Main Methods:

  • Literature review of medicinal chemistry studies on PDE4 inhibitors.
  • Analysis of structure-activity relationships (SAR) for different chemical classes.
  • Assessment of binding properties, enzyme kinetics, and selectivity profiles.
  • Evaluation of preclinical and clinical data regarding therapeutic applications.

Main Results:

  • Summary of various chemical classes of PDE4 inhibitors developed.
  • Correlation between structural features and PDE4 inhibitory activity.
  • Discussion of selectivity challenges and strategies to achieve target specificity.
  • Overview of the therapeutic efficacy and safety profiles of leading candidates.

Conclusions:

  • Medicinal chemistry has significantly advanced PDE4 inhibitor development.
  • Understanding structure-activity relationships is crucial for optimizing efficacy and selectivity.
  • PDE4 inhibitors hold promise as therapeutic agents for inflammatory and autoimmune conditions.
  • Continued research is essential for translating these inhibitors into effective clinical treatments.